Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cancer Related Cognitive Decline × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 241 Neoplasms 154 Breast Neoplasms 152 Colorectal Neoplasms 143 Melanoma 114 Neoplasm Metastasis 112 Prostatic Neoplasms 111 Ovarian Neoplasms 108 Leukemia, Myeloid, Acute 107 Recurrence 98 Pancreatic Neoplasms 95 Multiple Myeloma 95 Squamous Cell Carcinoma of Head and Neck 85 Lung Neoplasms 85 Stomach Neoplasms 84 Lymphoma 77 Lymphoma, Non-Hodgkin 75 Triple Negative Breast Neoplasms 73 Glioblastoma 73 Lymphoma, Large B-Cell, Diffuse 63 Carcinoma, Renal Cell 63 Precursor Cell Lymphoblastic Leukemia-Lymphoma 62 Endometrial Neoplasms 56 Advanced Solid Tumor 55 Leukemia, Lymphocytic, Chronic, B-Cell 50 Leukemia 50 Carcinoma, Hepatocellular 47 Uterine Cervical Neoplasms 46 Myelodysplastic Syndromes 46 Head and Neck Neoplasms 46

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡